



UNIVERSITI PUTRA MALAYSIA

***TOBRAMYCIN AND GENTAMICIN-INCORPORATED CALCIUM
PHOSPHATE BEADS AS DELIVERY SYSTEM IN PREVENTION OF
Staphylococcus aureus BIOFILM FORMATION***

CHE NOR ZARIDA CHE SEMAN


FPSK(M) 2012 55

**TOBRAMYCIN AND GENTAMICIN-INCORPORATED CALCIUM
PHOSPHATE BEADS AS DELIVERY SYSTEM IN PREVENTION OF
Staphylococcus aureus BIOFILM FORMATION**



**Thesis Submitted to the School of Graduate Studies,
Universiti Putra Malaysia,
in Fulfillment of the Requirements for the Degree of Master of Science**

June 2012



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of
the requirement for the degree of Master of Science

**TOBRAMYCIN AND GENTAMICIN-INCORPORATED CALCIUM
PHOSPHATE BEADS AS DELIVERY SYSTEM IN PREVENTION OF
Staphylococcus aureus BIOFILM FORMATION**

By

CHE NOR ZARIDA CHE SEMAN

June 2012

Chairman : Professor Fauziah Othman, PhD

Faculty : Faculty of Medicine and Health Sciences

Staphylococcus aureus (*S. aureus*) is the most common organism causing osteomyelitis which is associated with biofilm formation. This infection is difficult to treat, usually requires prolong administration of antibiotics and extensive surgical procedure. In order to eradicate biofilm formation, biomaterial incorporated with suitable antibiotics can be used as a preventative measure. Therefore, this study was conducted to assess the antibacterial properties of tobramycin and gentamicin-incorporated calcium phosphate beads in prevention of *S. aureus* biofilm formation.

In this present study, the live event for development of *S. aureus* biofilm was viewed under live cell imaging system and the morphology of biofilm was viewed under scanning electron microscopy (SEM). These microscopic studies showed that the biofilm formation involved initial attachment to a solid surface, the formation of microcolonies,

and finally differentiation of microcolonies into exopolysaccharide-encased as matured biofilm.

The 3(4, 5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was used to assess the efficacy of tobramycin and gentamicin-incorporated calcium phosphate beads against *S. aureus* biofilm. There was a significant difference between tobramycin-incorporated calcium phosphate beads and gentamicin-incorporated calcium phosphate beads on cell viability of *S. aureus* biofilm ($p<0.05$). Gentamicin-incorporated calcium phosphate beads showed the strongest action to inhibit *S. aureus* with IC₅₀ value of 0.05 mg/ml compared to tobramycin-incorporated calcium phosphate beads with IC₅₀ of 0.12 mg/ml. Fluorescence staining with acridine orange and propidium iodide (AOPI) showed that the live bacterial cells appeared green and dead cells appeared red-orange.

Ninhydrin assay was used to investigate the elution of tobramycin and gentamicin from the calcium phosphate carrier. The standard graphs for tobramycin and gentamicin solution versus absorbance reading were prepared as references to identify the concentration of the antibiotics release after incorporating calcium phosphate beads at the time points of 0.5 hour, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours, 48 hours, 72 hours, 168 hours (1 week), 336 hours (2 weeks), 672 hours (4 weeks) and 1344 hours (8 weeks).

The release of tobramycin from calcium phosphate beads was significantly different with gentamicin ($F_{group} = 175.54 > F_{0.05, 1, 2} = 18.51$). The release of gentamicin from calcium phosphate beads was higher than tobramycin. Furthermore, cumulative release of tobramycin and gentamicin from calcium phosphate beads showed that there was a

significant difference in the mean concentration of drug release at 1344 hours (8 weeks) between tobramycin-incorporated calcium phosphate beads and gentamicin-incorporated calcium phosphate beads ($p<0.001$). The mean cumulative release of gentamicin from calcium phosphate beads (249.3 (2.4) $\mu\text{g/ml}$) was higher than tobramycin (178.7 (4.1)) at 1344 hours.

The cytotoxicity test using MTT assay showed that osteoblast demonstrated good cell viability at the highest concentration of either 25 mg/ml tobramycin or 25 mg/ml gentamicin. There was a significant difference between tobramycin-incorporated calcium phosphate beads and gentamicin-incorporated calcium phosphate beads towards cell viability ($p<0.05$). Tobramycin-incorporated calcium phosphate beads was more cytotoxic on osteoblast than gentamicin-incorporated calcium phosphate beads. Moreover, investigation on the cell morphology and cell adherence by using SEM and CLSM showed that seeded cells were well attached to the tobramycin and gentamicin-incorporated calcium phosphate beads and continue to grow throughout the 5 days period.

In conclusion, tobramycin and gentamicin-incorporated calcium phosphate beads have the potential to be used as a new local drug delivery system in the prevention and treatment of bone infections. Furthermore, tobramycin and gentamicin-incorporated calcium phosphate beads scaffold could serve as a promising platform for the regeneration of osteoid tissues because of their slow release of antibiotic, biocompatibility and biodegradability.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai
memenuhi keperluan untuk Ijazah Master Sains

**SISTEM PENGHANTARAN TOBRAMISIN DAN GENTAMISIN –
TERGABUNG KALSIUM FOSFAT DALAM PENCEGAHAN PEMBENTUKAN
BIOFILEM**

Oleh

CHE NOR ZARIDA CHE SEMAN

Jun 2012

Pengerusi : Profesor Fauziah Othman, PhD

Fakulti : Fakulti Perubatan dan Sains Kesihatan

Staphylococcus aureus (*S. aureus*) adalah organisma yang paling biasa menyebabkan osteomielitis di mana ia dikaitkan dengan pembentukan biofilem. Jangkitan ini adalah sukar untuk dirawat, biasanya memerlukan rawatan antibiotik berpanjangan dan prosedur pembedahan yang ekstensif. Dalam usaha untuk membasmi pembentukan biofilem, biobahan digabungkan dengan antibiotik yang sesuai boleh digunakan sebagai langkah pencegahan. Kajian ini telah dijalankan untuk menilai ciri-ciri antibakteria manik tobramycin dan gentamicin-tergabung kalsium fosfat dalam pencegahan pembentukan *S. aureus* biofilem.

Dalam kajian ini, pembentukan *S. aureus* biofilem secara lansung telah dilihat di bawah sistem pengimejan sel hidup dan morfologi biofilem telah dilihat di bawah

mikroskop elektron imbasan (SEM). Kajian-kajian mikroskopik menunjukkan pembentukan biofilem melibatkan pelekatan awal pada permukaan, pembentukan mikrokoloni dan pembezaan mikrokoloni kepada eksopolisakarida sebagai biofilem yang matang.

Asai 3(4, 5-dimethylthiazole-2-YL)-2,5-diphenyl tetrazolium bromide (MTT) telah digunakan untuk menguji keberkesanan manik tobramisin dan gentamisin-tergabung kalsium fosfat terhadap biofilem *S. aureus*. Manik tobramisin-tergabung kalsium fosfat adalah berbeza secara signifikan berbanding manik gentamisin-tergabung kalsium fosfat dari segi kemandirian biofilem *S. aureus* ($p<0.05$). Manik gentamisin-tergabung kalsium fosfat menunjukkan tindakan yang lebih kuat untuk menghalang biofilem *S. aureus* dengan nilai IC_{50} 0.05 mg/ml berbanding manik tobramisin-tergabung kalsium fosfat dengan nilai IC_{50} 0.12 mg/ml. Pewarnaan floresen dengan akridina jingga dan propidium iodida (AOPI) menunjukkan bahawa sel-sel bakteria yang hidup kelihatan hijau dan sel-sel mati kelihatan merah oren.

Asai Ninhidrin telah digunakan untuk mengesan elusi tobramisin dan gentamisin daripada manik kalsium fosfat. Graf piawai untuk larutan tobramisin dan gentamisin melawan bacaan ketumpatan optik (OD) telah disediakan sebagai rujukan untuk mengenal pasti kepekatan antibiotik yang dielusikan melalui kalsium fosfat mengikut titik masa yang telah ditentukan iaitu 0.5 jam, 1 jam, 2 jam, 4 jam, 6 jam, 24 jam, 48 jam, 72 jam, 168 jam (1 minggu), 336 jam (2 minggu), 672 jam (4 minggu) and 1344 jam (8 minggu). Pelepasan tobramisin daripada manik kalsium fosfat adalah berbeza secara

signifikan dengan pelepasan gentamisin ($F_{group} = 175.54 > F_{0.05, 1, 2} = 18.51$). Gentamisin yang dilepaskan dari manik kalsium fosfat adalah lebih tinggi berbanding tobramisin. Selain itu, pelepasan kumulatif tobramisin dan gentamicin daripada manik kalsium fosfat pada 1344 jam (8 minggu) adalah berbeza secara signifikan ($p <0.001$). Pelepasan kumulatif min gentamisin daripada manik kalsium fosfat (249,3 (2.4) $\mu\text{g} / \text{ml}$) adalah lebih tinggi daripada tobramycin (178,7 (4,1)) pada 1344 jam.

Ujian bioserasi menggunakan asei MTT menunjukkan kemandirian osteoblast yang bagus pada kepekatan yang tinggi sama ada 25 mg/ml tobramisin atau 25 mg/ml gentamisin. Kemandirian sel selepas dirawat dengan manik tobramisin-tergabung kalsium fosfat adalah berbeza secara signifikan dengan manik gentamisin-tergabung kalsium fosfat ($p<0.05$). Manik tobramycin-tergabung kalsium fosfat adalah lebih sitotoksik terhadap osteoblast berbanding manik gentamicin-tergabung kalsium fosfat. Selanjutnya, kajian tentang morfologi dan pelekatan sel pada permukaan manik tobramisin dan gentamicin-tergabung kalsium fosfat dengan menggunakan SEM dan CLSM menunjukkan bahawa sel yang dikultur adalah melekat dan membiak pada permukaan bahan tersebut dalam tempoh 5 hari pengeraman.

Kesimpulannya, manik tobramisin dan gentamisin-tergabung kalsium fosfat mempunyai potensi sebagai sistem penghantaran antibiotik yang baru untuk mencegah dan merawat jangkitan tulang. Selain itu, manik tobramisin dan gentamisin-tergabung kalsium fosfat

boleh menjanjikan platform untuk regenerasi tisu osteoid kerana pembebasan antibiotik secara perlahan daripada kalsium fosfat, bioserasi dan biodegradasi.

ACKNOWLEDGEMENTS

In the name of Allah, the Most Merciful and Beneficent....first and foremost, all praised be Allah for giving me this wonderful opportunity to pursue my master programme, without whose blessing, I will not be here with my supervisors and fellow colleagues at UPM.

I am heartily thankful to my supervisor, Professor Dr. Fauziah Othman, whose encouragement, guidance and support from the initial to the final level enabled me to develop an understanding of this research. Her talents, dedication, and enthusiasm for research will be a continuing source of inspiration.

I gratefully appreciate the guidance of my supervisor committee, Associate Professor Dr. Arifah Abdul Kadir and Dr. Azfar Rizal Ahmad for gave their insight in their area of expertise in editing my thesis to become more scientific sounded and scientific grounded. I also would like to extend my appreciation to collaborator members, Associate Professor Dr. Ahmad Hafiz Zulkifly, Associate Professor Dr. Nazri Mohd Yusof from International Islamic University Malaysia (IIUM), Dr. Mohd Azam Khan Goriman Khan from Universiti Malaysia Kelantan (UMK) for all guidance, comments and suggestions that

helped me to overcome many difficulties in my research and also Pn. Rusnah Mustafa from Malaysian Nuclear Agency (MNA) who helps me to prepare antibiotic beads.

I would like to express my utmost thanks and appreciation to Dr. Niazlin Mohd Taib who gave me the chance to work in her Media Preparation Laboratory and Microbiology Laboratory. I would like to extend my sincere thanks to all staff at Microscopy Unit, Institute of Bioscience, Universiti Putra Malaysia (UPM) and Microscopy Unit, Faculty of Pharmacy, Universiti Teknologi MARA (UiTM) for helping me out with the microscopy imaging and their excellence services. I gratefully acknowledge MicroLambda Sdn Bhd for providing Live Cell Imaging System with the expert technical help. Further, I wish to thank Assoc. Prof. Dr. Saidi Moin and Hasni Idayu Saidi for taking the trouble to guide me in the statistical analysis.

With the biggest contribution to this thesis, I would like to thank IIUM for approving almost 3 years study leave and provided scholarship for me. Many special thank to UPM for sponsoring the research under Research University Grant Scheme (RUGS). Without their financial support, this research would be impossible.

Many thanks also go to my colleagues and friends for their advices and opinions. I wish to extend my final thanks to my family, especially my mum, Maimunah Abd Rahman, Ummi Teh and Cik Su without your love and support, I would not be here. Thank you very much for being by my side and putting up with me during the good and bad times.

Lastly, I offer my regards and blessings to all of those who supported me in any respect during the completion of the project.

I certify that a Thesis Examination Committee has met on 15th June 2012 to conduct the final examination of Che Nor Zarida Che Seman on her thesis entitled “Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads As Delivery System in Prevention of *Staphylococcus aureus* Biofilm Formation” in accordance with the Universities and University Colleges Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The Committee recommends that the student be awarded the Master of Science.

Members of the Thesis Examination Committee were as follows:

Asmah binti Rahmat, PhD

Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Chairman)

Saleha binti Abdul Aziz, PhD

Professor

Faculty of Veterinary Medicine

Universiti Putra Malaysia

(Internal Examiner)

Rokiah binti Mohd Yusof, PhD

Associate Professor

Faculty of Medicine and Health Sciences

Universiti Putra Malaysia

(Internal Examiner)

Nurina binti Anuar, PhD

Associate Professor

Faculty of Engineering and Built Environment

Universiti Kebangsaan Malaysia

(External Examiner)

SEOW HENG FONG, PhD

Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 27 September 2012

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Fauziah Othman, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairperson)

Arifah Abdul Kadir, PhD

Associate Professor
Faculty of Veterinary Medicine
Universiti Putra Malaysia
(Member)

Azfar Rizal Ahmad, MBBS

Lecturer
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies

Universiti Putra Malaysia

Date:

DECLARATION

I declare that the thesis is my original work except for quotations and citations, which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.

CHE NOR ZARIDA CHE SEMAN

Date: 15 June 2012

TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	v
ACKNOWLEDGEMENTS	viii
APPROVAL	x
DECLARATION	xii
LIST OF TABLES	xvi
LIST OF FIGURES	xvii
LIST OF ABBREVIATIONS	xx
 CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	
2.1 Osteomyelitis	6
2.2 Biofilm	8
2.2.1 Bacterial Biofilm Infections	11
2.2.2 Mechanism of Biofilm Resistance to Antimicrobial Agents	13
2.2.3 Mechanism of Biofilm Resistance to Host Immune System	15
2.3 <i>Staphylococcus aureus</i>	16
2.3.1 Methicillin-Resistant <i>Staphylococcus aureus</i>	18
2.3.2 Measuring the Bacteria Growth	19
2.4 Antibiotic Incorporated Biomaterial/ Local Antibiotic Therapy	21
2.4.1 Tobramycin Sulphate	24
2.4.2 Gentamicin Sulphate	26
2.5 Biomaterial	28
2.5.1 Calcium Phosphate	29
2.5.2 Injectable Synthetic Bone Substitute	34
2.6 Elution of Antibiotic Incorporated Biomaterial	35
2.7 Human Fetal Osteoblastic Cell Line	37
2.8 MTT Assay	39
2.9 Microscopic Approaches in Biomaterial Research	41
3 MATERIALS AND METHODS	
3.1 Experimental Study Design	46
3.2 Calcium Phosphate	48
3.2.1 Preparation of Calcium Phosphate Beads	48
3.3 <i>In vitro</i> Bacterial Biofilm	51

3.3.1	Bacterial Strains	51
3.3.2	Developing Catheter Associated Biofilm	51
3.3.3	Microtiter Plate Assay	53
3.3.4	Statistical Analysis	54
3.4	Antibiotic Susceptibility Test	
3.4.1	Minimum Inhibitory Concentration Assays	54
3.4.2	Antibiotic Disk Susceptibility Test (Kirby-Bauer Disk Diffusion)	55
3.4.3	Statistical Analysis	56
3.5	Antibiotic Elution Study	
3.5.1	Ninhydrin Assay	57
3.5.2	<i>In vitro</i> Release Tests of Tobramycin and Gentamicin from Calcium Phosphate Beads	58
3.5.3	Statistical Analysis	58
3.6	Cell Culture Studies	
3.6.1	Human Osteoblast Cell Line	59
3.6.2	<i>In vitro</i> Cytotoxicity Testing in Human Osteoblast Cell Line	60
3.6.3	Osteoblasts on Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads	60
3.6.4	Statistical Analysis	61
3.7	Specimen Processing for Microscopic Studies	
3.7.1	Live Cell Imaging System	61
3.7.2	Scanning Electron Microscopy	62
3.7.3	Confocal Laser Scanning Microscopy	64

4

RESULTS

4.1	Microscopic Evaluation of <i>S. aureus</i> Biofilm	
4.1.1	Live Cell Imaging System of <i>S. aureus</i> Biofilm Formation	66
4.1.2	Scanning Electron Microscopy of <i>S. aureus</i> Biofilm Formation	68
4.2	Antibacterial Activity of Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads	
4.2.1	Minimum Inhibitory Concentration Assays of Tobramycin on <i>S. aureus</i>	71
4.2.2	Minimum Inhibitory Concentration Assays of Gentamicin on <i>S. aureus</i>	74
4.2.3	Antibiotic Disk Susceptibility Test (Kirby-Bauer Disk-Diffusion) for Tobramycin	77
4.2.4	Antibiotic Disk Susceptibility Test (Kirby-Bauer Disk-Diffusion) for Gentamicin	81
4.2.5	Antibacterial Activity of Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads using Microtiter Plate Assay	85

	4.2.6 Microscopic Evaluation of Antibacterial Activity of Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads on <i>S. aureus</i> Biofilm	86
4.3	Drug Elution Study	
	4.3.1 Quantification Analysis of Tobramycin and Gentamicin	89
	4.3.2 <i>In vitro</i> Tobramycin and Gentamicin Release from Calcium Phosphate Bead	91
	4.3.3 Cumulative <i>In vitro</i> Release of Tobramycin and Gentamicin from Calcium Phosphate Bead	93
	4.3.4 Surface Characteristic of Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads During Ninhydrin Assay	94
4.4	Cell Culture Studies	
	4.4.1 <i>In vitro</i> Cytotoxicity Testing in Human Osteoblast Cell Line	98
	4.4.2 Osteoblasts on Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads	100
5	DISCUSSION	
	5.1 Microscopic Evaluation of <i>S. aureus</i> Biofilm	106
	5.2 Antibacterial Activity of Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads	109
	5.3 Elution and Dissolution of Tobramycin and Gentamicin from Calcium Phosphate Beads	113
	5.4 Cytotoxicity of Osteoblast on Tobramycin and Gentamicin-incorporated Calcium Phosphate Beads	116
6	CONCLUSIONS AND FUTURE RESEARCH RECOMMENDATION	119
	REFERENCES	123
	APPENDICES	140
	APPENDIX A: NINHYDRIN ASSAY	140
	APPENDIX B: CELL CULTURE	141
	APPENDIX C: BASIC CHEMICAL PREPARATIONS OF BIOLOGICAL SPECIMEN PROCESSING FOR SEM	142
	APPENDIX D : STATISTICAL ANALYSIS	143
	BIODATA OF STUDENT	158
	LIST OF PUBLICATIONS	159

LIST OF TABLES

Table		Page
2.1	Calcium phosphate as drug carrier for different drug and calcium phosphate formulation.	33
2.2	Varies microscopy approaches in biomaterial research.	43
4.1	Antibacterial activity of tobramycin on <i>S. aureus</i> determined by visual inspection and measuring optical density.	73
4.2	Antibacterial activity of gentamicin on <i>S. aureus</i> determined by visual inspection and measuring optical density.	76
4.3	The interpretation of inhibition zone diameter (mm) for tobramycin disks on the strains of <i>S. aureus</i> .	78
4.4	The interpretation of inhibition zone diameter (mm) for gentamicin disks on the strains of <i>S. aureus</i> .	82
4.5	Viability of <i>S. aureus</i> biofilm at 0 hour and 8 hours post-treatment with tobramycin and gentamicin-incorporated calcium phosphate beads.	87
4.6	Morphology description of tobramycin and gentamicin-incorporated calcium phosphate beads before (0 hour) and after (1344 hours) the ninhydrin assay.	95

LIST OF FIGURES

Figure		Page
2.1	Steps in biofilm formation.	9
2.2	Planktonic bacteria can be cleared by antibodies and phagocytes, and are susceptible to antibiotics.	12
2.3	Antibodies, antibiotics and phagocytes can access the bacteria within these communities, but the host phagocytes cannot engulf and kill the bacteria.	12
2.4	Serial dilution method.	20
2.5	Molecular structure of tobramycin sulphate.	24
2.6	Molecular structure of gentamicin sulphate.	27
2.7	Injectable Synthetic Bone Substitute (Jectos)	35
2.8	The reduction of MTT to formazan, which is a blue-magenta coloured crystal.	40
3.1	An overview of the experimental study design.	47
3.2	Steps for preparation of calcium phosphate beads.	49
3.3	Steps for preparation of calcium phosphate beads incorporated with antibiotics.	50
3.4	Component of a 14-gauge Teflon intravenous catheter.	52
4.1	Phase contrast micrographs of live biofilm formation by <i>S. aureus</i> at 6-hours post-inoculation, 7-hours post-inoculation, 8-hours post-inoculation and 9 to 10-hours post-inoculation.	67
4.2	Scanning electron micrographs of <i>S. aureus</i> biofilm on the surface of catheters from 1 to 9 days incubation.	69
4.3	Scanning electron micrographs of <i>S. aureus</i> biofilm on the surface of catheters from 13 to 17 days incubation.	70
4.4	Gross observation of MIC using 9 bijou bottles with each bottles contained 2 ml of difference concentrations of tobramycin and 2 ml of bacterial suspension.	72

Figure	Page
4.5 Gross observation of MIC using 9 bijou bottles with each bottles contained 2 ml of difference concentrations of gentamicin and 2 ml of bacterial suspension.	75
4.6 Petri dishes containing Mueller Hinton agar media with different concentrations of tobramycin disk (0.02 mg/ml, 0.04 mg/ml, 0.06 mg/ml, 0.08 mg/ml, 0.1 mg/ml and 1 mg/ml).	79
4.7 Petri dishes containing Mueller Hinton agar media with different concentrations of tobramycin disk (2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml and 10 mg/ml).	80
4.8 Petri dishes containing Mueller Hinton agar media with different concentrations of gentamicin disk (0.02 mg/ml, 0.04 mg/ml, 0.06 mg/ml, 0.08 mg/ml, 0.1 mg/ml and 1 mg/ml).	83
4.9 Petri dishes containing Mueller Hinton agar media with different concentrations of gentamicin disk (2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml and 10 mg/ml).	84
4.10 Effect of tobramycin-incorporated calcium phosphate beads and gentamicin-incorporated calcium phosphate beads on <i>S. aureus</i> biofilm viability.	86
4.11 Confocal laser scanning micrographs of <i>S.aureus</i> biofilm.	88
4.12 Standard curve for absorbance reading versus concentration of tobramycin	90
4.13 Standard curve for absorbance reading versus concentration of gentamicin	90
4.14 Concentration of tobramycin and gentamicin release from calcium phosphate bead over each sampling interval for the 8 weeks study period.	92
4.15 Cumulative <i>in vitro</i> release of tobramycin and gentamicin from calcium phosphate bead over each sampling interval for the 8 weeks study period.	94
4.16 Scanning electron micrographs of the surface of tobramycin-incorporated calcium phosphate beads.	96

Figure		Page
4.17	Scanning electron micrographs of the surface of gentamicin-incorporated calcium phosphate beads.	97
4.18	Cytotoxicity of tobramycin-incorporated calcium phosphate beads and gentamicin-incorporated calcium phosphate beads to osteoblast.	99
4.19	Scanning electron micrographs of human osteoblasts morphologies on tobramycin-incorporated calcium phosphate beads.	101
4.20	Scanning electron micrographs of human osteoblasts morphologies on gentamicin-incorporated calcium phosphate beads.	102
4.21	Confocal micrographs of human osteoblasts cultured on tobramycin-incorporated calcium phosphate beads at 1 day, 3 days and 5 days.	104
4.22	Confocal micrographs of human osteoblasts cultured on gentamicin-incorporated calcium phosphate beads at 1 day, 3 days and 5 days.	105



LIST OF ABBREVIATIONS

ADAHF-PRC	American Dental Association Health Foundation Paffenbarger Research Center
AO	Acridine orange
AOPI	Acridine orange-propidium iodide
ATP	Adenosine triphosphate
BSE	back-scattered electrons
β -TCP	Beta-tricalcium phosphate
Ca ²⁺	Calcium ion
CaP	Calcium phosphate
CFU	Colony forming unit
CHA	Carbonated hydroxyapatite
CLSM	Confocal laser scanning microscope
CNS	Central nervous system
CPD	Critical point drying
DCPD	Dicalcium phosphate dehydrate
DDS	Drug delivery system
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
ELISA	Enzyme-linked immunosorbent assay
EMIT	Enzyme-immunoassay
EPS	Extracellular polymeric substances
GFP	Green fluorescent protein

HA	Hydroxyapatite
hFOB 1.19	Human fetal osteoblastic cell line
HMDS	Hexamethyldisilazane
IC ₅₀	Inhibitory concentration of 50
IIUM	International Islamic University Malaysia
LB	Luria Bertani
MHA	Mueller-Hinton Agar
MHB	Mueller-Hinton Broth
MIC	Minimal inhibitory concentration
MNA	Malaysian Nuclear Agency
MTT	3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoliumbromide
NCCLS	National Committee for Clinical Laboratory Standards
OD	Optical density
PBS	Phosphate-buffered saline
PFIA	Polarization fluorescence immunoassay
PI	Propidium iodide
PMMA	Polymethylmethacrylate
PO ₄ ³⁻	Orthophosphate
P ₂ O ₇ ⁴⁻	Metaphosphate or pyrophosphate
rpm	Revolution per minute
SEM	Scanning electron microscope
SPSS	Statistical Package for the Social Sciences
TCP	Tricalcium phosphate

TDX	Fluorescence-immunoassay
TSA	Trypticase soy agar
UiTM	Universiti Teknologi MARA
UMK	Universiti Malaysia Kelantan
UPM	Universiti Putra Malaysia
UV	Ultraviolet
VIS	Visible



CHAPTER 1

INTRODUCTION

A biofilm is a thick community of bacteria that is attached to a substratum, interface or to each other and embedded in a matrix of extracellular polymeric substances (EPS). In the biofilm, bacteria are protected against environmental stresses, antimicrobial treatment, and the host immune system (Cortes *et al.*, 2011). Biofilms have been implicated in a variety of human infections, such as endocarditis, osteomyelitis, chronic otitis media, foreign-body-associated infections, gastrointestinal ulcers, urinary tract infections, chronic lung infections in cystic fibrosis patients, caries, and periodontitis (Costerton *et al.*, 1999). Biofilm-associated infections involved the different Gram-positive species of *Staphylococcus*, *Streptococcus* and *Enterococcus* as well as Gram-negative bacteria, such as *Pseudomonas aeruginosa*, *Escherichia coli* and *Actinobacillus actinomycetemcomitans* (Heilman and Got, 2010).

Staphylococcus aureus is the most common organism isolated in bone infection (osteomyelitis). Methicillin-resistant *S. aureus* (MRSA) infections are particularly difficult to treat. Antibiotic treatment of osteomyelitis is traditionally administered intravenously. However, oral regimens for osteomyelitis have been successfully tested in human trials but the choice of oral antimicrobials is restricted when dealing with multidrug-resistant organisms, and this may require the use of parenteral drugs (Yin *et al.*, 2005). Long-term parenteral antibiotics with multiple surgical debridements are often required for effective therapy (Lazzarini *et al.*, 2004) but, repeated failures of these

therapies often result in the removal of the orthopaedic implants which is costly and traumatic to the patient.

In orthopaedics, parenteral administration of antibiotics does not provide good local bone response due to poor vascularisation of cortical bone and low drug penetration. As an alternative, antibiotic-incorporated bone cement beads are specifically designed and directly implanted to the infected bone to combat infection localized in bone and bone tissue (Le Ray *et al.*, 2005). Antibiotic-incorporated bone cement beads provide high local concentration of antimicrobial agents in a limited blood circulation area and also in the infected dead space but the total dose of antibiotic applied locally are normally not sufficient to produce systemic effects. Thus, using a delivery system or carrier such as beads, a high local concentration of antibiotic can be attained and release slowly without exposing the patient to systemic toxic antibiotic levels, which could result in toxic site effect. Furthermore, due to the slow penetration, antibiotics that absorb into the biofilm matrix could have retarded bacteria penetration (Shigeta *et al.*, 1997). Hence, the *in situ* drug delivery system using calcium phosphate is tested for the slow-release of antibiotics.

Tobramycin and gentamicin are used most frequently by surgeons for incorporation into bone cement in Europe and United States (Kanellakopoulou and Giamarellos-Bourboulis, 2000; Walenkamp, 1997). This choice of antibiotics arose from the early work incorporating antibiotic in bone cement for the prophylaxis infection in total hip arthroplasty in 1970 (Nandi *et al.*, 2009b). Gentamicin remains the most effective antibiotic to incorporate with bone cement due to its high solubility, heat stability and

bactericidal activity at low concentration (Campoccia *et al.*, 2010; Faber *et al.*, 2005). This drug was selected in this study because it is widely used for the treatment of osteomyelitis. Meanwhile, tobramycin is closely related to gentamicin with a similar spectrum of activity against both Gram-positive and Gram-negative bacteria (Randelli *et al.*, 2010), but less ototoxic and nephrotoxic than gentamicin (Scott *et al.*, 1999) and its elution characteristics has been shown to elute at higher concentrations than gentamicin in bone cements (Sterling *et al.*, 2003; Malchau *et al.*, 2000). Furthermore, tobramycin is usually substituted for gentamicin, because it is available as a pharmaceutical-grade powder, whereas gentamicin is not (Wininger and Fass, 1996).

Calcium phosphate is excellent material for bone repair and regeneration because of its chemical compositions is similar to the mineral phase of natural bone (Gazdag *et al.*, 1995). In fact, calcium phosphate material serve as a mineral reservoir for calcium and phosphorus as does the role of a true bone. It is containing both calcium and phosphorus ions that help to enrich the surrounding microenvironment by degradation process which stimulates osteogenesis (LeGeros, 1993). Calcium phosphate has been given considerable attention in clinical usage and reported to have bioactivity, biocompatibility, osteointegrative, osteoconductive and osteophilic nature properties (Nandi *et al.*, 2009a; Mickiewicz, 2001; Moore *et al.*, 2001).

Generally, orthopaedic surgeons in Malaysia use gentamycin-incorporated polymethylmethacrylate (PMMA) chain or *Septopal* in the treatment of bone and soft-tissue infections. Although the use of gentamicin-incorporated PMMA beads is

acceptable in clinical practice, but PMMA beads are preferable to microorganism adherence and growth on the biomaterial surface, despite, the release of antibiotics and it also has potential to develop antibiotic resistance (Neut *et al.*, 2001). Besides that, a secondary surgery may be required to remove the cement because it is not biodegradable and may become a nidus for future infections (Liu *et al.*, 2007a). Therefore, in this study, tobramycin and gentamicin-incorporated calcium phosphate beads have been designed to be used as a new local drug delivery system in prevention of *S. aureus* biofilm formation as well as a bone replacement or implant. The bacteria were chosen since it was the most common organism that caused infection in orthopaedic practice (Calhoun and Mader, 1989).

1.1 Objectives of the research

General objective:

The general objective of this study is to assess the antibacterial properties of tobramycin and gentamicin-incorporated calcium phosphate beads as delivery system in prevention of *S. aureus* biofilm formation.

Specific objectives:

- To evaluate the development of *S. aureus* biofilm on glass slide and catheter.
- To assess the efficacy of the tobramycin and gentamicin-incorporated calcium phosphate beads against common etiological pathogen of osteomyelitis namely *S. aureus*.
- To investigate the elution of tobramycin and gentamicin from the calcium phosphate carrier (*in vitro*).
- To determine the cytotoxicity effect of tobramycin and gentamicin-incorporated calcium phosphate beads on bone tissue (*in vitro*).

REFERENCES

- Ahimou, F., Semmen, M.J., Haugstad, G. and Novak, P.J. 2007. Effect of protein, polysaccharide, and oxygen concentration profiles on biofilm cohesiveness. *Applied and Environmental Microbiology* 73: 2905–2910.
- Alt, V., Bechert, T., Steinrucke, P., Wagener, M., Seidel, P., Dingeldein, E., Domann, E. and Schnettler, R. 2004. *In vitro* testing of antimicrobial activity of bone cement. *Antimicrobial Agents and Chemotherapy* 48: 4084-4088.
- Alexis, F. 2005. Review factors affecting the degradation and drug-release mechanism of poly(lactic acid) and poly[(lactic acid)-co-(glycolic acid)]. *Polymer International* 54: 36-46.
- Amato, I., Ciapetti, G., Pagani, S., Marletta, G., Satriano, C., Baldini, N. and Granchi, D. 2007. Expression of cell adhesion receptors in human osteoblasts cultured on biofunctionalized poly-(ϵ -caprolactone) surfaces. *Biomaterials* 28: 3668-3678.
- Anagnostakos, K., Wilmes, P., Schmitt, E. and Kelm, J. 2009. Elution of gentamicin and vancomycin from polymethylmethacrylate beads and hip spacers *in vivo*. *Acta Orthopaedica* 80: 193-197.
- Anonymous. 2011a. Antibiotic Disk Susceptibilities (Kirby-Bauer Disk-Diffusion Method)<http://www.life.umd.edu/classroom/bsci424/LabMaterialsMethods/AntibioticDisk.htm>. Accessed on 13th May 2011.
- Anonymous. 2011b. Gentamicin sulfate. <http://en.wikipedia.org/wiki/Gentamicin>. Accessed on 16th February 2011.
- Anonymous. 2011c. MTT assay. http://en.wikipedia.org/wiki/MTT_assay. Accessed on 9th January 2011.
- Anonymous. 2011d. Tobramycin sulfate. http://www.chemicalbook.com/ChemicalProductProperty_EN_CB6678801.htm. Accessed on 16th February 2011.
- Antunes, L.C.M., Ferreira, R.B.R., Buckner, M.M.C. and Brett Finlay, B. 2010. Quorum sensing in bacterial virulence. *Microbiology* 156: 2271-2282.
- Ara, J., Gans, Z., Sweeney, R. and Wolf, B. 1995. Dot ELISA for the rapid detection of gentamicin in milk. *Journal of Clinical Laboratory Analysis* 9: 320-324.

- Baker, A.S. and Greenham, L.W. 1988. Release of gentamicin from acrylic bone cement. Elution and diffusion studies. *Journal Bone and Joint Surgery* 70A:1551-1557.
- Bauer, R.W., Kirby, M.D.K, Sherris, J.C. and Turck, M. 1966. Antibiotic susceptibility testing by standard single disc diffusion method. *American Journal of Clinical Pathology* 45: 493-496.
- Bayston, R. and Milner, R.D. 1982. The sustained release of antimicrobial drugs from bone cement. An appraisal of laboratory investigations and their significance. *Journal Bone and Joint Surgery* 64B: 460-464.
- Black, J.G. 2005a. Microbiology: Principles and Explorations. In *An Introduction to Taxonomy: The Bacteria*, 6th Edition, pp 234. Virginia: John Wiley & Sons.
- Black, J.G. 2005b. Growth and culturing of bacteria. In *An Introduction to Taxonomy: The Bacteria*, 6th Edition, pp 150-152. Virginia: John Wiley & Sons.
- Blokhus, T.J., Termaat, M.F., Den Boer, F.C., Patka, P., Bakker, F.C. and Haarman, H.J. 2000. Properties of calcium phosphate ceramics in relation to their *in vivo* behavior. *The Journal of Trauma: Injury, Infection, and Critical Care* 48: 179-186.
- Bohner, M. 2001. Physical and chemical aspects of calcium phosphates used in spinal surgery. *European Spine Journal* 10: S114-S121.
- Bozzola, J.J. 2007. Conventional Specimen Preparation Techniques for Scanning Electron Microscopy of Biological Specimens. In *Electron Microscopy Methods and Protocols*, 2nd Edition, ed. J. Kuo, pp. 449-466. New Jersey: Humana Press.
- Brady, R. A., Leid, J. G., Calhoun, J. H., Costerton, J. W. and Shirtliff, M. E. 2008. Osteomylitis and the role of biofilms in chronic infection. *FEMS Immunology and Medical Microbiology* 52: 13-22.
- Brien, W.W., Salvati, E.A., Klein, R., Brause, B. and Stern, S. 1993. Antibiotic impregnated bone cement in total hip arthroplasty. *Clinical Orthopaedics and Related Research* 296: 242-248.
- Brooun, A., Liu, S. and Lewis, K. 2000. A dose-response study of antibiotic resistance in *Pseudomonas aeruginosa* biofilms. *Antimicrobial Agents and Chemotherapy* 44: 640-646.
- Cabanillas, P.F., Pena, E.D., Barrales-Rienda, J.M. and Frutos, G. 2000. Validation and *in vitro* characterization of antibiotic-loaded bone cement release. *International Journal of Pharmaceutics* 209: 15-26.

- Calhoun, J. H., and Mader, J. T. 1989. Antibiotic beads in the management of surgical infections. *American Journal of Surgery* 157: 443-449.
- Campoccia, D., Montanaro, L., Speziale, P. and Arciola, C.R. 2010. Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. *Biomaterials* 31: 6363-6377.
- Chavez de Paz, L.E., Hamilton, I.R. and Svensater, G. 2008. Oral bacteria in biofilms exhibit slow reactivation from nutrient deprivation. *Microbiology* 154: 1927-1938.
- Chen, N.T., Hong, H.Z., Hooper, D.C. and May, Jr. J.W. 1993. The effect of systemic antibiotic and antibiotic-impregnated polymethylmethacrylate beads on the bacterial clearance in wounds containing contaminated dead bone. *Plastic and Reconstructive Surgery* 92: 1305-1311.
- Cheung, H.S. and Haak, M.H. 1989. Growth of osteoblasts on porous calcium phosphate ceramic: An *in vitro* model for biocompatibility study. *Biomaterial* 10: 63-67.
- Chow, L.C. 2009. Next generation calcium phosphate-based biomaterials. *Dental Materials Journals* 28: 1-10.
- Chow, L.C. and Takagi, S. 2001. A natural bone cement—A laboratory novelty led to the development of revolutionary new biomaterials. *Journal of Research of the National Institute of Standards and Technology* 106: 1029-1033.
- CLSI. 2009. Performance standards for antimicrobial disk susceptibility tests: Approved standard M02-A10, 10th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
- Clutterbuck, A.L., Woods, E.J., Knottenbelt, D.C., Clegg, P.D., Cochrane, C.A. and Pervical, S.L. 2007. Biofilms and their relevance to veterinary medicine. *Veterinary Microbiology* 121: 1-17.
- Cortés, M.E., Bonilla, J.C. and Sinisterra, R.D. 2011. Biofilm formation, control and novel strategies for eradication. *Formatex 2011*, 896-905.
- Costerton, J.W., Stewart, P.S. and Greenberg, E.P. 1999. Bacterial biofilms: A common cause of persistent infections. *Science* 284: 1318-1322.
- Cramton, S. and Gotz, F. 2004. Biofilm Development in *Staphylococcus*. In *Microbial Biofilms*, eds. M.A. Ghannoum and G.A. O'Toole, pp. 64-84. Washington, DC: ASM Press.
- Cunningham, A., Demarest, G., Rosen, P. and DeCoster, T.A. 2000. Antibiotic Bead Production. *The Iowa Orthopaedic Journal* 20: 31-35.

- Curtis, A. and Wilkinson, C. 1997. Topographical control of cells. *Biomaterial* 18: 1573-1583.
- Daculsi, G., Bouler, J.M. and LeGeros, R.Z. 1997. Adaptive crystal formation in normal and pathological calcifications in synthetic calcium phosphate and related biomaterials. *International Review of Cytology* 172: 129-191.
- Daculsi G. and Passuti N. 1990. Effect of the macroporosity for osseous substitution of calcium phosphate ceramics. *Biomaterials* 11: 86-87.
- Dash, A.K. 1996. Tobramycin. *Analytical Profiles of Drug Substances and Excipients* 24: 579-613.
- Donlan, R.M. 2001. Biofilms and device-associated infections. *Emerging Infectious Diseases* 7: 277-281.
- Du, J., Jasti, B. and Vasavada, R.C. 1997. Controlled release of tobramycin sulfate from poly(ortho esters) implantable discs for the treatment of osteomyelitis. *Journal of Controlled Release* 43: 223-233.
- Duncan, C.P. and Masri, B. 1993. Antibiotic depots. *Journal Bone and Joint Surgery [Br]* 75-B: 349-350.
- Desai, M., Buhler, T., Weller, P.H. and Brown, M.R. 1998. Increasing resistance of planktonic and biofilm cultures of *Burkholderia cepacia* to ciprofloxacin and ceftazidime during exponential growth. *Journal of Antimicrobial Chemotherapy* 42: 153-160.
- DiCicco, M., Goldfinger, A., Guirand, F., Abdullah A. and Jansen, S.A. 2004. *In vitro* tobramycin elution analysis from a novel β -tricalcium phosphate-silicate-xerogel biodegradable drug-delivery system. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 70: 1-20.
- DiCicco, M. Duong, T., Chu, A. and Jansen, S.A. 2003. Tobramycin and gentamycin elution analysis between two *in-situ* polymerizable orthopedic composites. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 65B: 137-149.
- Diekema, D.J., Pfaller, M.A., Schmitz, F.J., Smayevsky, J., Bell, J., Jones, R.N., Beach, M. 2001. Survey of infections due to *Staphylococcus* species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clinical Infectious Diseases* 32: S114 -S132.

- Drenkard, E. 2003. Antimicrobial resistance of *Pseudomonas aeruginosa* biofilms. *Microbes and Infection* 5: 1213-1219.
- Engesaeter, L.B., Lie, S.A., Espehaug, B., Furnes, O., Vollset, S.E. and Havelin, L.I. 2003. Antibiotic prophylaxis in total hip arthroplasty: Effects of antibiotic prophylaxis systemically and in bone cement on the revision rate of 22,170 primary hip replacements followed 0-14 years in the Norwegian Arthroplasty Register. *Acta Orthopaedica Scandinavica* 74: 644-651.
- Eniwumide, J.O., Yuan, H., Cartmell, S.H., Meijer, G.J. and de Bruijn, J.D. 2007. Ectopic bone formation in bone marrow stem cell seeded calcium phosphate scaffolds as compared to autograft and (cell seeded) allograft. *European Cell Material* 14: 30-38.
- Ethell, M.T., Bennett, R.A., Brown, M.P., Merritt, K., Davidson, J.S. and Tran, T. 2000. *In vitro* elution of gentamicin, amikacin and ceftiofur from polymethylmethacrylate and hydroxyapatite cement. *Veterinary Surgery* 29: 375–382.
- Faber, C., Stallmann, H.P., Lyaruu, D.M., Joosten, U., von Eiff, C., Nieuw Amerongen, A.V. and Wuisman, P.I.J.M. 2005. Comparable efficacies of the antimicrobial peptide human lactoferrin 1-11 and gentamicin in a chronic methicillin-resistant *Staphylococcus aureus* osteomyelitis model. *Antimicrobial Agents and Chemotherapy* 49: 2438-2444.
- Fellah, B.H., Gauthier, O., Weiss, P., Chappard, D. and Layrolle, P. 2008. Osteogenicity of biphasic calcium phosphate ceramics and bone autograft in a goat model. *Biomaterials* 29: 1177-1188.
- Fini, M., Giavaresia, G., Aldinia, N.N., Torricellia, P., Botterb, R., Berutob, D. and Giardino, R. 2002. A bone substitute composed of polymethylmethacrylate and α -tricalcium phosphate: results in terms of osteoblast function and bone tissue formation. *Biomaterials* 23: 4523-4531.
- Forsythe, M.E., Crawford, S., Sterling, G.J., Whitehouse, S.L. and Crawford, R. 2006. Safeness of Simplex-tobramycin bone cement in patients with renal dysfunction undergoing total hip replacement. *Journal of Orthopaedic Surgery* 14: 38-42.
- Freimoser, F.M., Jakob, C.A., Aebi, M. and Tuor, U. 1999. The MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) assay is a fast and reliable method for colorimetric determination of fungal cell densities. *Applied and Environmental Microbiology* 65: 3727-3729.
- Freshney, R.I. 2005. Cytotoxicity. In *Culture of Animal Cells: A Manual of Basic Technique*. 5th Edition, pp. 365-367. New York: Wiley-Liss.

- Frutos, P., Torrado, S., Perez-Lorenzo, M.E. and Frutos, G. 2000. A validated quantitative colorimetric assay for gentamicin. *Journal of Pharmaceutical and Biomedical Analysis* 21: 1149-1159.
- Ganderton, L., Chawla, J., Winters, C., Wimpenny, J. and Stickler, D. 1992. Scanning electron microscopy of bacterial biofilms on indwelling bladder catheters. *European Journal of Clinical Microbiology and Infectious Diseases* 11: 789-796.
- Galucci, N., Oliva, M., Carezzano, E., Zygadlo, J. and Demo, M. 2010. Terpenes antimicrobial activity against slime producing and non-producing staphylococci. *Molecular Medicinal Chemistry* 21: 132-136.
- Gauthier, O., Bouler, J.M., Aguado, E., Pilet, P. and Daculsi, G. 1998. Microporous biphasic calcium phosphate ceramic: Influence of macropore diameter and macroporosity percentage on bone ingrowth. *Biomaterial* 19: 133-139.
- Gautier, H., Daculsi, G. and Merle, C. 2001. Association of vancomycin and calcium phosphate by dynamic compaction: *In vitro* characterization and microbiological activity. *Biomaterials* 22: 2481-2487.
- Gazdag, A.R., Lane, J.M, Glaser, D. and Forster, R.A. 1995. Alternatives to autogenous bone graft: Efficacy and indications. *Journal of the American Academy Orthopaedic Surgeons* 3: 1-8.
- George, A. O'Toole and Kolter, R. 1998. Flagellar and twitching motility are necessary for *Pseudomonas aeruginosa* biofilm development. *Molecular Microbiology* 30: 295-304.
- Goldstein, J., Newbury, D., Joy, D., Lyman, C., Echlin, P., Lifshin, E., Sawyer, L. and Michael, J. 2003. *Scanning Electron Microscopy and X-ray Microanalysis*. 3rd Edition, pp. 1-17. New York: Springer Science.
- Gotz, F., Bannerman, T. and Schleifer, sn K-H. 2006. The Genera *Staphylococcus* and *Macrococcus*. In: *The Prokaryotes: A Handbook on the Biology of Bacteria: Firmicutes: Firmicutes with Low GC Content of DNA*, 3rd Edition, eds. M. Dworkin, S. Falkow, E. Rosenberg, K-H. Schleifer, and E. Stackebrandt, pp. 5-17, New York: Springer.
- Gough, J.E., Notingher, I. and Hench, L.L. 2004. Osteoblast attachment and mineralized nodule formation on rough and smooth 45S5 bioactive glass monoliths. *Journal of Biomedical Materials Research Part A* 68: 640-650.
- Gurtler, F., Kaltsatos, V., Boisrame, B., Deleforge, J., Gex-Fabry, M., Balant, L.P. and Gurny, R. 1995. Ocular availability of gentamicin in small animals after topical administration of a conventional eye drop solution and a novel long acting bioadhesive. *Ophthalmic Drug Insert Pharmaceutical Research* 12: 1791-1794.

- Hall-Stoodley, L., Costerton, J.W. and Stoodley, P. 2004. Bacterial biofilms: from the natural environment to infectious diseases. *Nature Reviews Microbiology* 2: 95-108.
- Harris, S.A., Enger, R.J., Riggs, B.L. and Spelsberg, T.C. 1995. Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. *Journal of Bone and Mineral Research* 10: 178-186.
- Heck, D., Rosenberg, A., Schink-Ascani, M., Garbus, S. and Kiewitt, T. 1995. Use of antibiotic-impregnated cement during hip and knee arthroplasty in the United States. *Journal of Arthroplasty* 10: 470-475.
- Heilman, C. and Got, F. 2010. Cell-cell communication and biofilm formation in Gram positive bacteria. In *Bacterial signalling*, eds. R. Kramer & K. Jung, pp. 7-22, Wiley-Blackwell: Weinheim.
- Heilmann, C., Hussain, M., Peters, G. and Gotz, F. 1997. Evidence for autolysin mediated primary attachment of *Staphylococcus epidermidis* to a polystyrene surface. *Molecular Microbiology* 24:1013-24.
- Huang, Y., Liu, C.S., Shao, H.F. and Liu, Z.J. 2000. Study on the applied properties of tobramycin-loaded calcium phosphate cement. *Key Engineering Materials* 192: 853-860.
- Inglis, J.J.T., Tit-Meng, L., Mah-Lee, N., Ee-Koon, T. and Kok-Pheng, H. 1995. Structural features of tracheal tube biofilm formed during prolonged mechanical ventilation. *CHEST* 108: 1049-1052.
- Ishida, H., Ishida, Y., Kurosaka, Y., Otani, T., Sato, K. and Kobayashi, H. 1998. *In vitro* and *in vivo* activities of levofloxacin against biofilm-producing *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* 42: 1641-1645.
- Jayaraman, M., Meyer, U., Buhner, M., Joos, U. and Wiesmann, H. 2004. Influence of titanium surfaces on attachment of osteoblast-like cells *in vitro*. *Biomaterials* 25: 625-631.
- Jindong, Z., Hai, T., Junchao, G., Bo, W., Li, B. and Qiang, W.B. 2010. Evaluation of a novel osteoporotic drug delivery system *in vitro*: Alendronate-loaded calcium phosphate cement. *Orthopaedics* 33: 561-570.
- Kadurugamuwa, J.L., Sin, L., Albert, E., Yu, J., Francis, K., DeBoer, M., Rubin, M., Bellinger-Kawahara, C., Parr, T.R., Jr. and Contag, P.R. 2003. Direct continuous method for monitoring biofilm infection in a mouse model. *Infection and Immunity* 71: 882-890.

- Kaito, C. and Sekimizu, K. 2007. Colony spreading in *Staphylococcus aureus*. *Journal of Bacteriology* 189: 2553-2557.
- Kaveh, K., Ibrahim, R., Abu Bakar, M.Z. and Ibrahim, T.A. 2010. Bone grafting and bone graft substitutes. *Journal of Animal and Veterinary Advances* 9: 1055-1069.
- Kawada-Matsuo, M. and Komatsuzawa, H. 2012. Factors affecting susceptibility of *Staphylococcus aureus* to antibacterial agents. *Journal of Oral Biosciences*, 54: 86-91.
- Kanellakopoulou, K. and Giamparellos-Bourboulis, E.J. 2000. Carrier systems for the local delivery of antibiotics in bone infections. *Drugs* 59: 1223-1232.
- Kania, R.E., Lamers, G.E., Van de Laar, N., Dijkhuizen, M., Lagendijk, E., Huy, P.T., Herman, P., Hiemstra, P., Grotea, J.J., Frijns, J. and Bloemberg, G.V. 2010. Biofilms on tracheoesophageal voice prostheses: A confocal laser scanning microscopy demonstration of mixed bacterial and yeast biofilms. *Biofouling* 26: 519-526.
- Kania, R.E., Lamers, G.E.M., Vonk, M.J., Huy, P.T.B., Hiemstra, P.S., Bloemberg, G.V. and Grote, J.J. 2007. Demonstration of bacterial cells and glycocalyx in biofilms on human tonsils. *Arch Otolaryngol Head Neck Surgery* 133: 115-121.
- Klekamp, J., Dawson, J.M., Haas, D.W., DeBoar, D. and Christie, M. 1999. The use of vancomycin and tobramycin in acrylic bone cement: Biomechanical effects and elution kinetics for use in joint arthroplasty. *Journal of Arthroplasty* 14: 339-346.
- Komath, M., Varma, H.K. and Sivakumar, R. 2000. On the development of an apatitic calcium phosphate bone cement. *Bulletin of Materials Science* 23: 135-140.
- Krisanapiboon, A. and Buranapanitkit, B. 2006. Biocompatibility of hydroxyapatite composite as a local drug delivery system. *Journal of Orthopaedic Surgery* 14: 315-318.
- Lane, J.M. and Bostrom, M.P. 1998. Bone grafting and new composite biosynthetic graft materials. *Instructional Course Lecture* 47: 525-534.
- Lawrence, J.R. and Neu, T.R. 1999. Confocal laser scanning microscopy for analysis of microbial biofilms. *Methods in Enzymology* 310: 131-144.
- Lazzarini, L., Mader, J. T. & Calhoun, J. H. 2004. Osteomyelitis in long bones. *Journal of Bone and Joint Surgery – American* 86-A, 2305–2318.
- Leid, J.G. 2009. Bacterial biofilms resist key host defenses. *Microbe* 4: 66-70.
- LeGeros, R.Z. 1993. Biodegradation and bioresorption of calcium phosphate ceramics. *Clinical Materials* 14: 65-68.

- Lembke, C., Podbielski, A., Hidalgo-Grass, C., Jonas, L., Hanski, E. and Kreikemeyer, B. 2006. Characterization of biofilm formation by clinically relevant serotypes of group A Streptococci. *Applied and Environmental Microbiology* 72: 2864-2875.
- Le Ray, A. M., Gautier, H., Laty, M. K., Daculsi, G., Merle, C., Jacqueline, C., Hamel, A. and Caillon, J. 2005. *In vitro* and *in vivo* bactericidal activities of vancomycin dispersed in porous biodegradable poly(ϵ -Caprolactone) microparticles. *Antimicrobial Agents and Chemotherapy* 49: 3025-3027.
- Lewis, K. 2001. Riddle of biofilm resistance. *Antimicrobial Agents and Chemotherapy* 45: 999-1007.
- Li, T., Bai, R. and Liu, J. 2008. Distribution and composition of extracellular polymeric substances in membrane-aerated biofilm. *Journal of Biotechnology* 135: 52-57.
- Liu, L., Chu, L., Liu, Q., Wang, C., Xia, Y. and Peng, X. 2010. A comparative study on biofilm formation of nontypeable *Haemophilus influenzae* and *Pseudomonas aeruginosa* under single culture or co-culture. *African Journal of Microbiology Research* 4:180-184.
- Liu, S.J., Chi P.S., Lin, S.S., Ueng, S.W.N., Chan, E.C. and Chen, J.K. 2007a. Novel solvent-free fabrication of biodegradable poly-lactic-glycolic acid (PLGA) capsules for antibiotics and rhBMP-2 delivery. *International Journal of Pharmaceutics* 330: 45-53.
- Liu, X., Lim, J.Y., Donahue, HJ, Dhurjati, R., Mastro, AM and Vogler EA. 2007b. Influence of substratum surface chemistry/energy and topography on the human fetal osteoblastic cell line hFOB 1.19: Phenotypic and genotypic responses observed *in vitro*. *Biomaterials* 28: 4535-4550.
- Liu, X., Ng, C. and Ferenci, T. 2000. Global adaptations resulting from high population densities in *Escherichia coli* cultures. *Journal of Bacteriology* 182: 4158-4164.
- Livermore, D.M., Winstanley, T.G. and Shannon, K.P. 2001. Interpretative reading: Recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. *Journal of Antimicrobial Chemotherapy* 48: 87-102.
- Lu, J., Descamps, M., Dejou, J., Kouibi, G., Hardouin, P., Lemaitre, J. and Proust, J.P. 2002. The biodegradation mechanism of calcium phosphate biomaterials in bone. *Journal of Biomedical Materials Research* 63: 408-412.
- Maathuis, P.G.M., Bulstra, S.K., Van der Mei, H.C., Van Horn, J.R. and Busscher, H.J. 2007. Biomaterial-associated Surgery and Infection: A Review of Literature. In *Biomaterials in Modern Medicine*, ed. G. Rakhorst, and R.J. Ploeg, pp. 17-43. Groningen: World Scientific.

- Mader, J.T., Ortiz, M. and Calhoun, J.H. 1996. Update on the diagnosis and management of osteomyelitis. *Clinics in Podiatric Medicine and Surgery* 13: 701-724.
- Malchau, H., Herberts, P., Soderman, P. and Oden, A. 2000. Prognosis of total hip replacement. Update and validation of results from the Swedish National Hip Arthroplasty Registry 1979-1998. *Proceedings of the 67th Annual Meeting of the American Academy of Orthopaedic Surgeons* 2000: 607.
- Magallanes-Perdomo, M., De Aza, A.H., Mateus, A.Y., Teixeira, S., Monteiro, F.J., De Aza, S. and Pena, P. 2010. *In vitro* study of the proliferation and growth of human bone marrow cells on apatite-wollastonite-2M glass ceramics. *Acta Biomaterialia* 6: 2254-2263.
- Mah, T.C. and O'Toole, G.A. 2001. Mechanisms of biofilm resistance to antimicrobial agents. *TRENDS in Microbiology* 9: 34-39.
- Mayr-Wohlfart, U., Fiedler, J., Gunther, K.P., Puhl, W. and Kessler, S. 2001. Proliferation and differentiation rates of a human osteoblast-like cell line (SaOS-2) in contact with different bone substitute materials. *Journal of Biomedical Materials Research* 57: 132-139.
- McKay, W.F. 2010. Implant depots to deliver growth factors to treat osteoporotic bone. <http://www.freepatentsonline.com/7833270.html>. Accessed on 2 January 2011.
- Mello, A., Hong, Z., Rossi, A.M., Luan, L., Farina, M., Querido, W., Eon, J., Terra, J., Balasundaram, G., Webster, T., Feinerman, A., Ellis, D.E., Ketterson, J.B. and Ferreira, C.L. 2007. Osteoblast proliferation on hydroxyapatite thin coatings produced by right angle magnetron sputtering. *Biomedical Materials* 2: 67-77.
- Mickiewicz, R.A. 2001. *Polymer-calcium phosphate composites for use as an injectable bone substitute*, PhD Thesis, Massachusetts Institute of Technology.
- Miglioli, P.A., Pea, F., Mazzo, M., Bert, T., Lanzafame, T. 1993. Possible influence of assay methods in studies of the pharmakokinetics of antibiotics. *Journal of Chemotherapy* 5: 27-31.
- Mingeot-Leclercq, M.P., Brasseur, R. and Schanck, A. 1995. Molecular parameters involved in aminoglycoside nephrotoxicity. *Journal of Toxicology and Environmental Health* 44: 263-300.
- Moore W.R., Graves S.E. and Bain, G.I. 2001. Synthetic bone graft substitutes. *ANZ Journal of Surgery* 71: 354-361.

- Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods* 65: 55-63.
- Morato, J., Codony, F. and Mas, J. 2004. Microscopy techniques applied for monitoring the development of aquatic biofilms. *Current Issues on Multidisciplinary Microscopy Research and Education*. Formatec: 93-100.
- Moreno, M.A., Frutos, P. and Ballesteros, M.P. 1998. Extraction and liquid chromatographic detection of Amphotericin B in oil-water Lecithin based micro emulsions. *Chromatographia* 48: 803-806.
- Mshana, R.N., Tadesse, G., Abate, G. and Miорнер, H. 1998. Use of 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant *Mycobacterium tuberculosis*. *Journal of Clinical Microbiology* 36: 1214-1219.
- Mueller, L.N., de Brouwer, J.F.C., Almeida, J.S., Stal, L.J. and Xavier, J.B. 2006. Analysis of a marine phototropic biofilm by confocal laser scanning microscopy using the new image quantification software PHLIP. *BioMed Central Ecology* 6: 1-15.
- Nandi, S.K., Kundu, B., Ghosh, S.K., Mandal, T.K., Datta, S., De, D.K. and Basu, D. 2009a. Cefuroxime-impregnated calcium phosphates as an implantable delivery system in experimental osteomyelitis. *Ceramic International* 35: 1367-1376.
- Nandi, S.K., Mukherjee, P., Roy, S., Kundu, B., De, D.K. and Basu, D. 2009b. Local antibiotic delivery systems for the treatment of osteomyelitis – A review. *Materials Science and Engineering: C* 29: 2478-2485.
- Naraharisetti, P.K., Lee, H.C.G., Fu, Y.C., Lee, D.J. and Wang, C.W. 2006. *In vitro* and *in vivo* release of gentamicin from biodegradable discs. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 77B: 329-337.
- Nelson, C.L., Griffin, F.M., Harrison, B.H. and Cooper, R.E. 1992. *In vitro* elution characteristics of commercially and noncommercially prepared antibiotic PMMA beads. *Clinical Orthopaedics and Related Research* 284: 303-309.
- Neut, D., Van de Belt, H., Stokroos, I., Van Horn, J.R., Van der Mei, H.C. and Busscher, H.J. 2001. Biomaterial-associated infection of gentamicin-loaded PMMA beads in orthopaedic revision surgery. *Journal of Antimicrobial Chemotherapy* 47: 885-891.
- Nijhof, M.W., Dhert, W.J.A., Tilman, P.B.J. and Verbout, A.J. 1997. Release of tobramycin from tobramycin-containing bone cement in bone and serum of rabbits. *Journal of Materials Science: Materials in Medicine* 8: 799-802.

- O'Brien F. 2011. Biomaterials and scaffolds for tissue engineering. <http://epubs.rcsi.ie/anatart/38/>. Accessed on 12th June 2011.
- O'Toole, G., Kaplan, H.B. and Kolter, R. 2000. Biofilm formation as microbial development. *Annual Review of Microbiology* 54: 49-79.
- Patton, T., Barrett, J., Brennan, J. and Moran, N. 2006. Use of a spectrophotometric bioassay for determination of microbial sensitivity to manuka honey. *Journal of Microbiological Methods* 64: 84-95.
- Price, J.S., Tencer, A.F., Arm, D.M. and Bohach, G.A. 1996. Controlled release of antibiotics from coated orthopaedic implants. *Journal of Biomedical Material Research*, 30: 281-286.
- Popham, G.J., Mangino, P., Seligson, D. and Henry, S.L. 1991. Antibiotic-impregnated beads. Part II: Factors in antibiotic selection. *Orthopedic Reviews* 20: 331-337.
- Prapan, S., Udomrat, S. and Puntheeranurak. T. 2009. Characterization of osteoblasts and biomineral formation by atomic force microscopy study. *Journal of Microscopy Society of Thailand* 23: 7-11.
- Randelli, P., Evola, F.R., Cabitza, P., Polli, L., Denti, M. and Vaienti, L. 2010. Prophylactic use of antibiotic-loaded bone cement in primary total knee replacement. *Knee Surgery, Sports Traumatology, Arthroscopy* 18: 181-186.
- Ratier, Gibson, I.R., Best, S.M., Freche, M., Lacout, J.L. and Rodriguez, F. 2001. Behaviour of a calcium phosphate bone cement containing tetracycline hydrochloride or tetracycline complexed with calcium ions. *Biomaterials* 22: 897-901.
- Ravelingien, M., Mullens, S., Luyten, J., D'Hondt, M., Boonen, J., De Spiegeleer, B., Coenye, T., Vervaet, C. and Remon, J.P. 2010. Vancomycin release from poly(D, L-lactic acid) spray-coated hydroxyapatite fibers. *European Journal of Pharmaceutics and Biopharmaceutics* 76: 366-370.
- Reamer, R.H., Dey, B.P., White, C.A. and Mageau, R.P., 1998. Comparison of monolayer and bilayer plates used in antibiotic assay. *Journal of AOAC International* 81: 398-402.
- Rohde, H., Burandt, E.C., Siemssen, N., Frommelt, L., Burdelski, C., Wurster, S., Scherpe, S., Davies, A.P., Harris, L.G., Horstkotte, M.A., Knobloch, J.K.M., Ragunath, C., Kaplan, J.B. and Mack, D. 2007. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of *Staphylococcus epidermidis* and *Staphylococcus aureus* isolated from prosthetic hip and knee joint infections. *Biomaterials* 28: 1711-1720.

- Rosa, A.L. and Beloti, M.M. 2003. Effect of cpTi surface roughness on human bone marrow cell attachment, proliferation, and differentiation. *Brazilian Dental Journal* 14: 16-21.
- Sadashivaiah, A.B and Mysore, V. 2010. Biofilms: Their role in dermal fillers. *Journal of Cutaneous and Aesthetic Surgery* 3: 20-22.
- Schmitt, S.C., Wiedmann-Al-Ahmad, M., Kuschnierz, S., Al-Ahmad, A., Huebner, U., Schmelzeisen, R and Gutw, R. 2008. Comparative *in vitro* study of the proliferation and growth of ovine osteoblast-like cells on various alloplastic biomaterials manufactured for augmentation and reconstruction of tissue or bone defects. *Journal of Material Science: Material Medicine* 19: 1441-1450.
- Schmitz, J.P., Hollinger, J.O. and Milam, S.B. 1999. Reconstruction of bone using calcium phosphate bone cements: A critical review. *Journal of Oral and Maxillofacial Surgery* 57: 1122-1126.
- Schnieders, J., Gbureckb, U., Thullb, R. and Kissela, T. 2006. Controlled release of gentamicin from calcium phosphate-poly(lactic acid-co-glycolic acid) composite bone cement. *Biomaterials* 27: 4239-4249.
- Scott, C.P., Higham, P.A. and Dumbleton, J.H. 1999. Effectiveness of bone cement containing tobramycin: An *in vitro* susceptibility study of 99 organisms found in infected joint arthroplasty. *Journal of Bone and Joint Surgery (Br)* 81-B: 440-443.
- Seligson, D., Popham, G. J., Voos, K., Hendry, S. L and Faghri, M. 1993. Antibiotic-leaching from polymethylmethacrylate beads. *The Journal of Bone and Joint Surgery* 75: 714-720.
- Shadomy, S. and Kirchoff, C. 1972. *In vitro* susceptibility testing with tobramycin. *Antimicrobial Agents and Chemotherapy* 1: 412-416.
- Shigeta, M., Tanaka, G., Komatsuzawa, H., Sugai, H., Suginaka, H. and Usui, T. 1997. Permeation of antimicrobial agents through *Pseudomonas aeruginosa* biofilms: A simple method. *Cancer Chemotherapy* 43: 340-345.
- Silverman, L.D., Lukashova, L., Herman, O.T., Lane, J.M. and Boskey, A.L. 2007. Release of gentamicin from a tricalcium phosphate bone implant. *Journal of Orthopaedic Research* 25: 23-29.
- Soto-Hall, R., Saenz, L., Tavernetti, R., Cabaud, H.E. and Cochran, T.P. 1983. Tobramycin in bone cement: An in depth analysis of wound, serum and urine concentrations in patients undergoing total hip revision arthroplasty. *Clinical Orthopaedics and Related Research* 175: 60-64.
- Stadtlander, C. 2007. Scanning Electron Microscopy and Transmission Electron Microscopy of Mollicutes: Challenges and Opportunities. In *Modern Research*

and Educational Topics in Microscopy, eds. A. Méndez-Vilas, and J. Díaz, pp. 122-131. Badajoz: Formatex.

- Stallmann, H.P., Faber, C., Bronckers, A.L.J.J., Amerongen, A.V.N. and Wuisman, P.I.J.M. 2004. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF-11 or gentamicin-containing calcium phosphate cement. *Journal of Antimicrobial Chemotherapy* 54: 472–476.
- Stead, D.A. and Richards, R.M. 1997. Sensitive high performance liquid chromatographic assay of aminoglycosides in biological matrices enables the direct estimation of bacterial drug uptake. *Journal of Chromatography B: Biomedical Science Applications* 2: 415-421.
- Sterling, G.J., Crawford, S., Potter, J.H., Koerbin, G. and Crawford, R. 2003. The pharmacokinetics of Simplex-tobramycin bone cement. *Journal of Bone and Joint Surgery (Br)* 85: 646-649.
- Stewart, J.W. and Costerton, J.W. 2001. Antibiotic resistance of bacteria of biofilms. *Lancet* 358: 135-138.
- Stigter, M., de Groot, K. and Layrolle, P. 2002. Incorporation of tobramycin into biomimetic hydroxyapatite coating on titanium. *Biomaterials* 23: 4143-4153.
- Susan, K., Mikota, D.V.M. and Plumb, D.C. 2003. Gentamicin sulfate. <http://www.elephantcare.org/Drugs/gentamic.htm>. Accessed on 22nd January 2011.
- Sutton, S. 2011. Measurement of microbial cells by optical density. *Journal of Validation Technology* 17: 46-49.
- Takechi, M., Miyamoto, Y., Momota, Y., Yuasa, T., Tatehara, S., Nagayama, M., Ishikawa, K. and Suzuki, K. 2002. The *in vitro* antibiotic release from anti-washout apatite cement using chitosan. *Journal of Materials Science: Materials in Medicine* 13: 973–978.
- Tam, V.H., Kabbara, S., Vo, G., Schilling, A.N. and Coyle, E.A. 2006. Comparative pharmacodynamics of gentamicin against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy* 50: 2626-2631.
- Tan, H.T., Rosliza, A.R., Gan, S.H., Ahmad Sukari, H., Siti Asma', H., Siti Amrah, S. and Kirnpal-Kaur, B.S. 2009. The antibacterial properties of Malaysian tualang honey against wound and enteric microorganisms in comparison to manuka honey. *BMC Complementary and Alternative Medicine* 9: 34-41.

- Teixeira, S., Ferraz, M.P. and Monteiro, F.J. 2008. Biocompatibility of highly macroporous ceramic scaffolds: Cell adhesion and morphology studies. *Journal of Materials Science: Materials in Medicine* 19: 855-859.
- Teixeira, T., Queiroz, A.C., Monteiro, F.J., Ferraz, M.P., Vilar, R. and Eugenio, S. 2006. Osteoblast proliferation and morphology analysis on laser modified hydroxyapatite surfaces: Preliminary results. *Key Engineering Materials* 309: 105-108.
- Teller, M., Gopp, U., Neumann, H.G. and Kuhn, K.D. 2006. Release of gentamicin from bone regenerative materials: An *in vitro* study. *Journal of Biomedical Materials Research Part B: Applied Biomaterials* 81B(1): 23-29.
- Tenke, P., Riedl, C.R., Jones G.L., Williams, G.J., Stickler, D and Nagy, E. 2004. Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy. *International Journal of Antimicrobial Agents* 23S1: S67-S74.
- Thornsberry, C. 1991. Antimicrobial Susceptibility Testing: General Considerations. In *Manual of Clinical Microbiology*, 5th Edition, ed. A. Balows, W. Houston, K.L. Hermann, H. Isenberg, pp. 1059-1064, Washington, DC: American Society for Microbiology.
- Todar, K. 2008. *Staphylococcus aureus* and Staphylococcal Disease. <http://www.textbookofbacteriology.net/staph.html>. Accessed on 11 November 2010.
- Van de Belt, H., Neut, D., Uges, D.R., Schenk, W., Van Horn, J.R., Van Der Mei, H.C. and Busscher, H.J. 2000. Surface roughness, porosity and wettability of gentamicin-loaded bone cements and their antibiotic release. *Biomaterial* 21: 1981-1887.
- Vallet-Regi, M., Ramila, A., Del Real, R.P. and Perez-Pariente, J., 2001. A new property of MCM-41: drug delivery system. *Chemistry of Materials* 13: 308-311.
- Verron, E., Khairoun, I., Guicheux, J. and Bouler, J.M. 2010. Calcium phosphate biomaterials as bone drug delivery system: A review. *Drug Delivery Today* 15: 547-552.
- Viswanath, B., Raghavan, R., Gurao, N.P., Ramamurty, U. and Ravishankar. 2008. Mechanical properties of tricalcium phosphate single crystals grown by molten salt synthesis. *Acta Biomaterialia* 4: 1448-1454.
- Von Recum, A.F. and LaBerge, M. 1995. Educational goals for biomaterials science and engineering: Perspective view. *Journal of Applied Biomaterials* 6: 137-144.

- Vuong, C., Kidder, J.B., Jacobson, E.R., Otto, M., Proctor, R.A and Somerville, G.A. 2005. *Staphylococcus epidermidis* polysaccharide intercellular adhesin production significantly increases during tricarboxylic acid cycle stress. *Journal of Bacteriology* 187: 2967–2973.
- Walenkamp, G.H. 1997. Chronic osteomyelitis. *Acta Orthopaedica Scandinavica* 68: 497-506.
- Walter, M.C., Roe, F., Bugnicourt, A., Franklin, M.J. and Stewart, P.S. 2003. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of *Pseudomonas aeruginosa* biofilms to ciprofloxacin and tobramycin. *Antimicrobial Agents and Chemotherapy* 47: 317-323.
- Wang, G., Liu, S.J., Ueng, S.W.N. and Chan, E.C., 2004. The release of cefazolin and gentamicin from biodegradable PLA/PGA beads. *International Journal of Pharmaceutics* 273: 203-212.
- Wentland, E.J., Steward, P.S., Huang, C-T. and McFeters, G.A. 1996. Spatial variations in growth rate within *Klebsiella pneumonia* colonies and biofilm. *Biotechnology Progress* 12: 316-321.
- Wahlig, H. and Dingeldein, E. 1980. Antibiotics and bone cements. Experimental and clinical long-term observations. *Acta Orthopaedica Scandinavica* 51: 49-56.
- Wahlig, H., Dingeldein, E., Bergmann, R. and Reuss, K. 1978. The release of gentamicin from polymethylmethacrylate beads. An experimental and pharmacokinetic study. *The Journal of Bone and Joint Surgery* 60: 270-275.
- Wei, G., Kotoura, Y., Oka, M. and Yamamoto, T. 1991. A bioabsorbable delivery system for antibiotic treatment of osteomyelitis. *Journal of Bone and Joint Surgery* 73-B: 246-252.
- Wichelhaus, T.A., Dingeldein, E., Rauschmann, M., Kluge, S., Dieterich, R., Schafer, V. and Brade, V. 2001. Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. *Journal of Antimicrobial Chemotherapy* 48: 117-119.
- Williams, S.C., Hong, Y., Danavall, D.C.A., Howard-Jones, M.H., Gibson, D., Frischer, M.E. and Verity, P.G. 1998. Distinguishing between living and nonliving bacteria: Evaluation of the vital stain propidium iodide and its combined use with molecular probes in aquatic samples. *Journal of Microbiological Methods* 32: 225-236.
- Wininger, D.A. and Fass, R.J. 1996. Antibiotic-impregnated cement and beads for orthopedic infections. *Antimicrobial Agents and Chemotherapy* 40: 2675-2679.

- Wu, S.C., Hsu, H.C., Hsu, S.K., Wang, W.H. and Ho, W.F. 2011. Preparation and characterization of four different compositions of calcium phosphate scaffolds for bone tissue engineering. *Material Characterization* 62: 526-534.
- Wu, B., Zhu, J.S., Zhang, Y., Shen, W.M. and Zhang, Q. 2008. Predictive value of MTT assay as an *in vitro* chemosensitivity testing for gastric cancer: One institution's experience. *World Journal of Gastroenterology* 14: 3064-3068.
- Xavier, D.E., Picão, R.C., Girardello, R., Fehlberg, L.C.C. and Gales, A.C. 2010. Efflux pumps expression and its association with porin down-regulation and β -lactamase production among *Pseudomonas aeruginosa* causing bloodstream infections in Brazil. *Microbiology* 10: 1-7.
- Xu, H.H.K., Quinn, J.B., Takagi, S. and Chow, L.C. 2002. Processing and properties of strong and non-rigid calcium phosphate cement. *Journal of Dental Research* 81: 219-224.
- Yamasaki, H. and Saki, H. 1992. Osteogenic response to porous hydroxyapatite ceramics under the skin of dogs. *Biomaterials* 13: 308-312.
- Yen, M.L., Chien, C.C., Chiu, I.M., Huang, H.I., Chen, Y.C., Hu, H.I. and Yen, B.L. 2007. Multilineage differentiation and characterization of the human fetal osteoblastic 1.19 cell line: A possible *in vitro* model of human mesenchymal progenitors. *Stem Cells* 25: 125-31.
- Yin, L.Y., Lazzarini, L., Li, F., Melinda Stevens, C. and Calhoun, J.H. 2005. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillinresistant *Staphylococcus aureus* experimental osteomyelitis in a rabbit model. *Journal of Antimicrobial Chemotherapy* 55: 995-1002.
- Yuan, H., Kurashina, K., De Bruijin, J.D., Li, Y., De Groot, K. and Zhang, X. 1999. A preliminary study on osteoinduction of two kinds of calcium phosphate ceramics. *Biomaterials* 20: 1799-1806.
- Zalavras, C.G., Patzakis, M.J. and Holtom, P. 2004. Local antibiotic therapy in the treatment of open fractures and osteomyelitis. *Clinical Orthopaedics and Related Research* 427: 86-93.
- Zhang, Y. and Zhang, M. 2002. Calcium phosphate/chitosan composite scaffolds for controlled *in vitro* antibiotic drug release. *Journal of Biomedical Materials Research* 62: 378-386.
- Zilberman, M. and Elsner, J.J. 2008. Antibiotic-eluting medical devices for various applications. *Journal of Controlled Release* 130: 202-215.